Literature DB >> 12358907

Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number.

Graham B Tennant1, Ala I Al-Sabah, Alan K Burnett.   

Abstract

Myelodysplastic (MDS) patients at diagnosis (n = 162) were analysed by the International Prognostic Scoring System (IPSS). The two intermediate groups were not significantly different. The IPSS was of limited value in predicting survival of MDS patients after preliminary separation into subgroups with < 5%, or >/= 5%, myeloblasts. Cox's proportional hazards analysis of these subgroups enabled discrimination of highly significant prognostic groups. In both subgroups, longer survival was associated with macrocytosis. Mean corpuscular volume (MCV) and marrow myeloblast number were used to define four groups with prognostic significance similar to the IPSS. A low-risk group was described by macrocytosis associated with < 5% myeloblasts and high risk was related to blast counts >/= 5% and MCV < 100 fl. Further analysis defined factors identifying very high-risk patients and those with benign disease, together with many intermediate survival patterns. Results were consistent in two time-separated patient groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358907     DOI: 10.1046/j.1365-2141.2002.03783.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Etanercept-induced leukemia: could increased mean corpuscular volume be a predictor of hematologic malignancy?

Authors:  Döndü Üsküdar Cansu; Hava Üsküdar Teke; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2017-03-02       Impact factor: 2.631

2.  Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Authors:  Naoki Shingai; Yuka Harada; Hiroko Iizuka; Yosuke Ogata; Noriko Doki; Kazuteru Ohashi; Masao Hagihara; Norio Komatsu; Hironori Harada
Journal:  Int J Hematol       Date:  2018-10-23       Impact factor: 2.490

3.  [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].

Authors:  Z X Shi; T J Qin; Z F Xu; H J Huang; B Li; S Q Qu; N B Hu; L J Pan; D Liu; Y N Cai; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

4.  A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features.

Authors:  Fengqi Liu; Hehua Wang; Junru Liu; Zhenhai Zhou; Dong Zheng; Beihui Huang; Chang Su; Waiyi Zou; Duorong Xu; Xiuzhen Tong; Juan Li
Journal:  Cancer Med       Date:  2019-07-19       Impact factor: 4.452

5.  The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.

Authors:  Panagiotis Diamantopoulos; Dafni Koumbi; Ioannis Kotsianidis; Vasiliki Pappa; Argiris Symeonidis; Athanasios Galanopoulos; Panagiotis Zikos; Helen A Papadaki; Panayiotis Panayiotidis; Maria Dimou; Eleftheria Hatzimichael; George Vassilopoulos; Susan Delimpasis; Despoina Mparmparousi; Sotirios Papageorgiou; Eleni Variami; Marie-Christine Kyrtsonis; Aekaterini Megalakaki; Maria Kotsopoulou; Panagiotis Repousis; Ioannis Adamopoulos; Flora Kontopidou; Dimitrios Christoulas; Alexandra Kourakli; Dimitrios Tsokanas; Menelaos Konstantinos Papoutselis; Georgios Kyriakakis; Nora-Athina Viniou
Journal:  Cancer Med       Date:  2019-03-21       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.